Remarkably, we found that the FASN-block effectively inhibited ICC progression in vitro, suggesting that it may have beneficial effects in patients with circMBOAT2-associated ICC (i.e., patients with elevated levels of circMBOAT2 expression). This evidence concerns the gene FASN and intrahepatic cholangiocarcinoma.